• On March 30, 2026, Butterfly Network announced it had secured FDA approval for its AI-powered handheld ultrasound tool that estimates gestational age to support clinicians in emergency and rural settings.
• This clearance highlights Butterfly’s effort to pair portable imaging hardware with embedded AI, aiming to broaden access to maternal care in underserved communities.
• We’ll now examine how FDA clearance of Butterfly’s gestational-age AI tool may influence its investment narrative and long-term digital-health ambitions.

Find 59 companies with promising cash flow potential yet trading below their fair value.

Butterfly Network Investment Narrative Recap

To own Butterfly Network, you need to believe handheld ultrasound and embedded AI can become a widely adopted, software-rich platform rather than a niche device. The new gestational-age FDA clearance reinforces the AI-in-a-probe story but does not directly change the most immediate catalyst, which is the upcoming Q1 2026 earnings update, or the biggest risk, which is still the company’s ongoing operating losses and cash burn.

The most relevant recent announcement is February’s raised 2026 revenue guidance to US$117 million to US$121 million, implying about 20 percent to 24 percent growth. That guidance was issued before the gestational-age AI approval, so investors will be watching closely to see whether management frames this new tool as incremental to that outlook or simply part of executing on the existing pipeline of enterprise, global health and Butterfly Garden AI initiatives.

Yet behind the excitement around FDA-cleared AI tools, investors still need to be aware of...

Butterfly Network's narrative projects $135.9 million revenue and $17.0 million earnings by 2028.

Uncover how Butterfly Network's forecasts yield a $5.56 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming revenue of about US$156.0 million by 2029 and ongoing losses, and they focus heavily on risks like persistent cash burn and slower software mix improvement. You may find that this new AI approval either challenges or reinforces those doubts, which is why it is worth comparing these more pessimistic views with your own expectations.

Explore 8 other fair value estimates on Butterfly Network - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Butterfly Network research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Butterfly Network research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Butterfly Network's overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.